YL-Pharma Overview
- Year Founded
-
2011
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
14
YL-Pharma General Information
Description
Developer of small chemical drugs for the treatment of cancer, autoimmune diseases and metabolic disorders. The company researches and develops innovative and best-in-class drugs for the treatment of cancer, autoimmune diseases and metabolic disorders, committing to serving unmet medical needs of patients.
Contact Information
Website
www.yl-pharma.comCorporate Office
- Building A7, Caohejing Kangqiao Business Oasis
- Number 2555 Xiupu Road, Pudong New District
- Shanghai, 201203
- China
Corporate Office
- Building A7, Caohejing Kangqiao Business Oasis
- Number 2555 Xiupu Road, Pudong New District
- Shanghai, 201203
- China
YL-Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 07-May-2026 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 14-Mar-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 08-Nov-2023 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 08-Feb-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 02-Feb-2021 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Jun-2016 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 12-May-2015 | Completed | Generating Revenue |
YL-Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
YL-Pharma Patents
YL-Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026108794-A1 | Heterocyclic compound, pharmaceutical composition thereof, and use thereof | Pending | 21-Nov-2024 | ||
| WO-2026077361-A1 | Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof, and use thereof | Pending | 12-Oct-2024 | ||
| WO-2025256469-A1 | Pharmaceutical composition and use thereof | Pending | 14-Jun-2024 | ||
| WO-2025179441-A1 | Compound with tricyclic structure, pharmaceutical composition thereof and use thereof | Pending | 27-Feb-2024 | ||
| WO-2025168048-A1 | Compound having triple bond structure, and pharmaceutical composition thereof and use thereof | Pending | 08-Feb-2024 |
YL-Pharma Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Anhui Zhongan Capital | Growth/Expansion | Minority | ||
| Shenzhen Yifeng Investment Management Enterprise | Venture Capital | Minority | ||
| CICC Capital | PE/Buyout | Minority | ||
| DYEE Capital | Asset Manager | Minority | ||
| Haiwang Capital | Venture Capital | Minority |
YL-Pharma FAQs
-
When was YL-Pharma founded?
YL-Pharma was founded in 2011.
-
Where is YL-Pharma headquartered?
YL-Pharma is headquartered in Shanghai, China.
-
What industry is YL-Pharma in?
YL-Pharma’s primary industry is Pharmaceuticals.
-
Is YL-Pharma a private or public company?
YL-Pharma is a Private company.
-
What is YL-Pharma’s current revenue?
The current revenue for YL-Pharma is .
-
How much funding has YL-Pharma raised over time?
YL-Pharma has raised $20M.
-
Who are YL-Pharma’s investors?
Anhui Zhongan Capital, Shenzhen Yifeng Investment Management Enterprise, CICC Capital, DYEE Capital, and Haiwang Capital are 5 of 14 investors who have invested in YL-Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
